Breaking News, Collaborations & Alliances

Biogen Expands Neurological Disease R&D

Enters deals with C4 Therapeutics and Skyhawk worth nearly $500 million when combined

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen and C4 Therapeutics have entered into a strategic collaboration to investigate the use of C4’s novel protein degradation platform to discover and develop potential new treatments for neurological conditions, such as Alzheimer’s disease and Parkinson’s disease.   C4 will provide expertise and research services in targeted protein degradation and Biogen will provide neuroscience expertise and drug development capabilities. Biogen and C4 will research potential targets together and Biogen ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters